Finch throws in the towel on microbiome journey, lets go of 77 employees
Finch Therapeutics’ attempt to make crapsules that help prevent the recurrence of a bacterial infection is nearing the end of the road.
For the third time in nine months, the Boston-area biotech will lay off staffers, this time 95%, which equates to 77 employees.
As is becoming more and more familiar in biotech these days, Finch flashed red lights early Tuesday, saying it will scrap a Phase III trial testing its donor stool-in-a-capsule for the prevention of recurring infection from the bacteria Clostridioides difficile, or C. diff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.